DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment




Rad Oncology Homepage

CMS to unveil mandatory payment model for radiation oncology Part of determining approach that saves more and offers greater quality

European report says radiotherapy 'undervalued' and needing 'greater investment' Equipment shortages, lack of investment, training variations

ViewRay to supply UK's GenesisCare with country's first MRIdian systems Providing soft-tissue imaging in real time and better tumor targeting

Precision cancer care with proton and radiation oncology Some of the latest systems and software entering the market

IBA Dosimetry debuts myQA Daily at ASTRO 2018 Has 125 ionization chamber measurement points

Accuray showcases software upgrades for CyberKnife and Radixact at ASTRO Allows for 40 percent faster treatment delivery

Siemens launches RT Pro edition of MAGNETOM Sola at ASTRO MR system assists in radiation therapy treatment planning

RaySearch introduces machine learning in RayStation at ASTRO First machine learning applications on RayStation platform

Brainlab debuts RT patient positioning and monitoring system at ASTRO Monitors both external and internal motion

New Philips MR and CT scanners debut at ASTRO CT system, Big Bore RT, and Ingenia MR-RT take aim at radiotherapy outcomes

Israeli startup Alpha Tau Medical raises $29 million for novel radiotherapy

by Thomas Dworetzky , Contributing Reporter
From the issue of DOTmed HealthCare Business News magazine

Alpha Tau Medical, developer of Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT), has raised $29 million in private money in a round led by Israeli private equity firm Shavit Capital.

The late-stage investor was part of a round that included crowdfunding platform, Medison Ventures, and Sir Ronald Cohen and Alan Patricof, founders of Apax Partners.

Story Continues Below Advertisement

New & Refurbished C-Arm Systems. Call 702.384.0085 Today!

KenQuest provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs

"We are excited by the strong support provided by these distinguished investors," Alpha Tau's CEO Uzi Sofer said in a statement. "The funding will be invaluable to explore the full potential of the Alpha DaRT as a cancer treatment for clinical trials worldwide, as well as establish global production facilities for the radioactive DaRT seeds to meet local distribution demand."

The investment comes on the heels of the Massachusetts Radiation Control Program (RCP), in conjunction with the U.S. Nuclear Regulatory Commission (NRC), approving Alpha DaRT cancer treatment as a Sealed Source and Device (SSD), and safe for clinical trials.

It is the first alpha radiation-based cancer treatment for various types of solid tumors, administering high-precision, soft-range alpha particles that effectively destroy cancer cells while sparing surrounding healthy tissue.

The particles are inserted into the tumor using ultra-minimally-invasive applicators created to reach various types of tumors in different anatomic areas.

As the radioactive material inside decays, it releases alpha radiation inside the tumor, breaking the DNA in ways that destroy cancer cells.

“The Alpha DaRT applicators are designed to ensure that the Alpha DaRT seeds and the radioactive isotopes will be released only inside of the tumor in a way that will eliminate the risk of unnecessary exposure to the patient or the medical staff,” Amnon Gat, chief operations officer for Alpha Tau Medical, told HCB News in August. “The sealing mechanisms of the Alpha DaRT devices were tested under extreme environmental conditions that are required by ISO 2919, such as high temperature, pressure, impact and bending."

Early clinical trials have shown that Alpha DaRT is safe and effective for squamous cell carcinoma tumors – with all patients seeing tumor reduction and over 70 percent having tumors disappear within days of therapy.

"We are confident that Alpha Tau's groundbreaking technology can be a game changer in the treatment of cancer,”said Shavit Capital founder and managing partner Gary Leibler, stressing that the firm's experienced team had succeeded in forming “strategic relationships and trials with leading international medical research centers,” which position it to become a global power in next-gen cancer radiation therapies.

Meir Jakobsohn, the founder and CEO of Medison Pharma – one of the firm's first investors – added that his firm was “very optimistic about the Alpha DaRT's potential to activate the immune system and to become a valid treatment option for metastatic cancer.”

Clinical trials are now underway for Alpha DaRT using varied protocols across a number of cancers, including pancreatic, breast, head and neck, gynecological, and prostate.

Rad Oncology Homepage

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to, Inc. Copyright ©2001-2018, Inc.